Pharmtrace klinische Entwicklung
Pharmtrace klinische Entwicklung is recorded as a service provider in 6 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 6 of 6 trials · Latest update first
An Open-Label, Randomized, Controlled Multi-Center Study of The Efficacy of Daromun (L19IL2 + L19TNF) Neoadjuvant Intratumoral Treatment Followed by Surgery and Adjuvant Therapy Versus Surgery and Adjuvant Therapy in Clinical Stage IIIB/C Melanoma Patients
Sponsor Philogen S.p.A.
- Start (EU)
- Latest update
- Estimated end
Prospective, Multi-Center Study to Assess the Diagnostic Performance of [18F]PSMA-1007 PET/CT Imaging in Patients with Newly-Diagnosed High-Risk or Very-High-Risk Prostate Cancer
Sponsor Abx Advanced Biochemical Compounds - Biomedizinische Forschungsreagenzien GmbH
- Start (EU)
- Latest update
- Estimated end
A Phase 2 Diagnostic Study with 68Ga-EVG321 in Patients with Small Cell Lung Cancer
Sponsor Evergreen Theragnostics Inc.
- Start (EU)
- Latest update
- Estimated end
A randomized open-label phase II study on the effect of durvalumab and tremelimumab combined with personalized SIRT (p-SIRT), standard-dose SIRT (sd-SIRT) or immunotherapy followed by on-demand loco-regional SIRT (od-SIRT) in non-resectable hepatocellular carcinoma (HCC) patients
Sponsor Klinikum der Universitaet Muenchen AöR
- Start (EU)
- Latest update
- Estimated end
- Not reported
An open-label, multi-center, non-randomized pivotal Phase 3 study to evaluate the efficacy and safety of [18F]florbetaben Positron Emission Tomography (PET) imaging to diagnose cardiac AL amyloidosis
Sponsor Lantheus Germany GmbH
- Start (EU)
- Latest update
- Estimated end
A pivotal Phase III, open-label, randomized, controlled multi-center study of the efficacy of L19IL2/L19TNF neoadjuvant intratumoral treatment followed by surgery versus surgery alone in clinical stage III B/C melanoma patients
Sponsor Philogen S.p.A.
- Start (EU)
- Latest update
- Estimated end
- Not reported
Questions about this trial experience
What services are recorded for Pharmtrace klinische Entwicklung?
The 2026-10-09 snapshot links Pharmtrace klinische Entwicklung to 6 distinct CTIS trials. Recorded services include Project management, Data management, Electronic data capture, Regulatory services, among 10 recorded service labels. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Pharmtrace klinische Entwicklung?
The most frequently recorded therapeutic areas are Solid Tumor Oncology, Dermatology, Respiratory, Urology. Recorded phases include Phase 3, Phase 2. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Pharmtrace klinische Entwicklung conducted?
The linked trials record locations in 8 countries, including Germany, Italy, Spain, France, Austria. These are trial locations, not confirmed office locations or countries where Pharmtrace klinische Entwicklung delivered services.
What can this page tell me about Pharmtrace klinische Entwicklung's trial experience?
Browse 6 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. No trial-level operational findings are recorded in this snapshot. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 2 recorded name variants under Pharmtrace klinische Entwicklung. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Pharmtrace Klinische Entwicklung GmbH
- Pharmtrace klinische Entwicklung GmbH